Log In

Forgot Password?

OR

Not a member? Continue as a nonmember.

Become a Member

By becoming a member of the AAN, you can receive exclusive information to help you at every stage of your career. Benefits include:

Join Now See All Benefits

Loading... please wait

Abstract Details

Long-term Survival in Multiple Sclerosis is Improving
Multiple Sclerosis
P5 - Poster Session 5 (11:45 AM-12:45 PM)
3-011
Long-term studies evaluating benefit from disease modifying therapy are few and the data on effects of treatment on survival in MS are limited. 

To study longitudinal survival probability by period of MS-diagnosis and time from disease onset to diagnosis using nation-wide data from the Nordic MS-registries.

All patients in the MS registries in Norway (N=11869), Sweden (N=20696), Denmark (N=21492) and Finland (N=17716) alive at the study starting point of Jan 1st 2000 were included in the study, with a follow-up time for up to 20 years. A total of 6333 deaths were recorded during the follow-up period ending Dec. 31st 2020. Long-term survival in MS patients was analyzed in each MS-registry cohort using Cox proportional hazards regression. Covariates included in the regression model were sex (ref:male), age at onset, calendar period of diagnosis (< 1980, 1981-1989, 1990-1999 (ref), >1999), MS phenotype at diagnosis (relapsing-remitting MS (ref), primary progressive MS) and diagnostic delay (time from MS onset to MS diagnosis in years: <2 (ref), 2-4, 5-10, > 10). Results were then combined and used in meta-analyses to identify common effects or variations as well as overall estimates using all four MS registries.

The overall estimated values for hazard ratios and 95% confidence intervals for sex were 0.66 [0.61, 0.71], for onset age 1.06 [1.05, 1.07], for MS phenotype 1.65 [1.44, 1.89], for period of diagnosis 4.95 [2.44, 10.07], 2.03 [1.49, 2.76], 0.48 [0.35, 0.65], and for diagnostic delay 1.37 [1.23, 1.52], 1.70 [1.55, 1.86], 3.52 [3.09, 4.00]. The estimated effects were all significant, while the test for heterogeneity was significant for diagnosis period and diagnostic delay.

In this study based on four nation-wise population-based Nordic MS-registries , we found that survival in MS has improved significantly over time depending on period of MS diagnosis, and that diagnostic delay significantly reduces survival probability.
Authors/Disclosures
Stig Wergeland, MD, PhD (Haukeland University Hospital)
PRESENTER
Dr. Wergeland has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Wergeland has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Janssen. Dr. Wergeland has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Sanofi. Dr. Wergeland has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Janssen. Dr. Wergeland has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biogen. The institution of Dr. Wergeland has received research support from Biogen.
Janne Mannseth, PhD Miss Mannseth has nothing to disclose.
Sari Atula, MD, PhD Sari Atula, MD, PhD has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Sari Atula, MD, PhD has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Sari Atula, MD, PhD has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB Pharma. Sari Atula, MD, PhD has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Sari Atula, MD, PhD has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Biogen.
Lars Forsberg Lars Forsberg has nothing to disclose.
Anna Glaser Anna Glaser has nothing to disclose.
Hanna Joensen (DMSR) Hanna Joensen has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen.
Melinda Magyari, MD Dr. Magyari has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Magyari has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Dr. Magyari has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Magyari has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Magyari has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Magyari has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Magyari has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Magyari has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Bristol Myers Squibb. The institution of Dr. Magyari has received research support from The Danish MS Society. The institution of Dr. Magyari has received research support from Biogen. The institution of Dr. Magyari has received research support from Novartis. The institution of Dr. Magyari has received research support from Roche. The institution of Dr. Magyari has received research support from Merck. The institution of Dr. Magyari has received research support from Sanofi.
Merja Soilu-Hanninen Merja Soilu-Hanninen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Merck. Merja Soilu-Hanninen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Merja Soilu-Hanninen has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi. The institution of Merja Soilu-Hanninen has received research support from Biogen.
Matias Viitala, Other (StellarQ Ltd.) Mr. Viitala has nothing to disclose.
Jan A. Hillert, MD (Karolinska Institute, Neurology R54) Dr. Hillert has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Hillert has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Celgene. Dr. Hillert has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Hillert has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Hillert has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sandoz. Dr. Hillert has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. The institution of Dr. Hillert has received research support from Biogen. The institution of Dr. Hillert has received research support from Celgene. The institution of Dr. Hillert has received research support from Merck. The institution of Dr. Hillert has received research support from Novartis. The institution of Dr. Hillert has received research support from Sanofi. The institution of Dr. Hillert has received research support from Roche.
Nina Grytten, PhD (University of Bergen) Dr. Grytten has nothing to disclose.